The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
MDS 2020 | Realigning MDS treatment goals
Mikkael Sekeres
• 5 Mar 2020
Mikkael Sekeres, MD, MS, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, discusses the challenges in drug development in myelodysplastic syndromes (MDS) with respect to aligning trial endpoints for lower and higher risk patients with treatment goals meaningful to patients. This interview took place at the 2nd Regional Symposium on Myelodysplastic Syndromes (MDS 2020), held in Tel Aviv, Israel.
